Q2 2023 Earnings Estimate for Catalent, Inc. Issued By Jefferies Financial Group (NYSE:CTLT)
Q2 2023 Earnings Estimate for Catalent, Inc. Issued By Jefferies Financial Group (NYSE:CTLT)
Catalent, Inc. (NYSE:CTLT – Get Rating) – Analysts at Jefferies Financial Group upped their Q2 2023 EPS estimates for shares of Catalent in a report released on Tuesday, January 24th. Jefferies Financial Group analyst D. Windley now expects that the company will earn $0.71 per share for the quarter, up from their previous estimate of $0.70. The consensus estimate for Catalent's current full-year earnings is $2.93 per share. Jefferies Financial Group also issued estimates for Catalent's Q3 2023 earnings at $0.86 EPS.
Catalent,Inc.(紐約證券交易所代碼:CTLT-GET Rating)-在1月24日星期二發佈的一份報告中,傑富瑞金融集團的分析師上調了對Catalent股票2023年第二季度每股收益的預期。傑富瑞金融集團分析師D.Windley現在預計,該公司本季度每股收益為0.71美元,高於此前預期的0.70美元。對Catalent目前全年收益的普遍預期為每股2.93美元。傑富瑞金融集團還發布了對Catalent 2023年第三季度每股收益的估計為0.86美元。
A number of other equities analysts also recently issued reports on CTLT. TheStreet downgraded shares of Catalent from a "b-" rating to a "c+" rating in a research note on Friday, October 28th. Bank of America cut shares of Catalent from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $125.00 to $60.00 in a report on Wednesday, November 2nd. Argus cut shares of Catalent from a "buy" rating to a "hold" rating in a report on Monday, November 7th. Royal Bank of Canada cut their price objective on shares of Catalent from $125.00 to $73.00 and set an "outperform" rating for the company in a report on Wednesday, November 2nd. Finally, Morgan Stanley cut their price objective on shares of Catalent from $120.00 to $81.00 and set an "overweight" rating for the company in a report on Thursday, November 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $92.40.
其他一些股票分析師最近也發佈了關於CTLT的報告。華爾街在10月28日星期五的一份研究報告中將Catalent的股票評級從“b-”下調至“c+”。美國銀行在11月2日(週三)的一份報告中將卡特倫特的股票評級從買入下調至中性,並將該股的目標價從125.00美元下調至60美元。在11月7日星期一的一份報告中,Argus將Catalent的股票評級從“買入”下調至“持有”。11月2日,加拿大皇家銀行在一份報告中將卡特倫特股票的目標價從125.00美元下調至73.0美元,併為該公司設定了“跑贏大盤”的評級。最後,摩根士丹利在11月3日週四的一份報告中將加泰羅蘭股票的目標價從120.00美元下調至81.00美元,併為該公司設定了“增持”評級。一位研究分析師對該股的評級為賣出,三位分析師給出了持有評級,五位分析師給出了該公司股票的買入評級。根據MarketBeat.com的數據,該股目前的普遍評級為持有,平均目標價為92.40美元。
Catalent Price Performance
催化劑的性價比
Catalent (NYSE:CTLT – Get Rating) last posted its quarterly earnings data on Tuesday, November 1st. The company reported $0.25 earnings per share for the quarter, missing analysts' consensus estimates of $0.49 by ($0.24). The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.06 billion. Catalent had a return on equity of 12.55% and a net margin of 8.83%.
Catalent(NYSE:CTLT-GET Rating)最近一次公佈季度收益數據是在11月1日星期二。該公司公佈本季度每股收益為0.25美元,低於分析師普遍預期的0.49美元(0.24美元)。該公司本季度營收為10.2億美元,高於分析師預期的10.6億美元。Catalent的股本回報率為12.55%,淨利潤率為8.83%。
Insiders Place Their Bets
內部人士下注
In other Catalent news, insider Ricky Hopson sold 643 shares of the business's stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $49.36, for a total transaction of $31,738.48. Following the completion of the transaction, the insider now owns 16,452 shares in the company, valued at approximately $812,070.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Manja Boerman sold 780 shares of the business's stock in a transaction on Monday, December 5th. The shares were sold at an average price of $51.70, for a total value of $40,326.00. Following the completion of the sale, the insider now directly owns 15,860 shares of the company's stock, valued at $819,962. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Ricky Hopson sold 643 shares of the business's stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $49.36, for a total transaction of $31,738.48. Following the completion of the sale, the insider now directly owns 16,452 shares of the company's stock, valued at $812,070.72. The disclosure for this sale can be found here. Insiders sold 3,874 shares of company stock worth $233,414 in the last 90 days. Corporate insiders own 0.58% of the company's stock.
在加泰羅尼亞的其他消息中,內部人士裏奇·霍普森在1月23日星期一的一筆交易中出售了643股該公司的股票。這些股票的平均價格為49.36美元,總成交額為31,738.48美元。交易完成後,這位內部人士現在擁有該公司16,452股股票,價值約812,070.72美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可在此超鏈接。在相關新聞中,內部人士Manja Boerman在12月5日星期一的一次交易中出售了780股該公司的股票。這些股票的平均價格為51.70美元,總價值為40,326.00美元。出售完成後,這位內部人士現在直接持有該公司15,860股股票,價值819,962美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接。此外,內部人士裏奇·霍普森在1月23日星期一的一次交易中出售了643股該公司的股票。這些股票的平均價格為49.36美元,總成交額為31,738.48美元。出售完成後,這位內部人士現在直接持有該公司16,452股股票,價值812,070.72美元。關於這次銷售的披露可以找到這裏。在過去的90天裏,內部人士出售了3874股公司股票,價值233,414美元。企業內部人士持有該公司0.58%的股份。
Institutional Investors Weigh In On Catalent
機構投資者看好Catalent
A number of institutional investors and hedge funds have recently bought and sold shares of CTLT. Tokio Marine Asset Management Co. Ltd. increased its stake in shares of Catalent by 22.5% during the second quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,043 shares of the company's stock worth $326,000 after acquiring an additional 558 shares during the period. US Bancorp DE grew its position in Catalent by 1.4% during the third quarter. US Bancorp DE now owns 19,237 shares of the company's stock worth $1,392,000 after buying an additional 272 shares during the period. Mitsubishi UFJ Trust & Banking Corp grew its position in Catalent by 12.0% during the second quarter. Mitsubishi UFJ Trust & Banking Corp now owns 90,954 shares of the company's stock worth $9,759,000 after buying an additional 9,723 shares during the period. Illinois Municipal Retirement Fund grew its position in Catalent by 88.1% during the second quarter. Illinois Municipal Retirement Fund now owns 6,028 shares of the company's stock worth $647,000 after buying an additional 2,824 shares during the period. Finally, Private Advisor Group LLC grew its position in Catalent by 98.5% during the second quarter. Private Advisor Group LLC now owns 5,870 shares of the company's stock worth $630,000 after buying an additional 2,913 shares during the period. 99.38% of the stock is owned by hedge funds and other institutional investors.
一些機構投資者和對衝基金最近買賣了CTLT的股票。東京海上資產管理公司在第二季度增持了22.5%的Catalent股票。東京海上資產管理有限公司在此期間增持了558股,目前持有該公司3,043股股票,價值326,000美元。US Bancorp DE在第三季度增加了1.4%的Catalent頭寸。US Bancorp DE現在擁有19,237股該公司股票,價值1,392,000美元,在此期間又購買了272股。三菱UFJ信託銀行(Mitsubishi UFJ Trust&Banking Corp)第二季度在Catalent的頭寸增加了12.0%。三菱UFJ信託銀行(Mitsubishi UFJ Trust&Banking Corp)目前持有90,954股該公司股票,價值9,759,000美元,在此期間又購買了9,723股。伊利諾伊市退休基金在第二季度將其在Catalent的頭寸增加了88.1%。伊利諾伊州市政退休基金現在擁有該公司6,028股股票,價值647,000美元,在此期間又購買了2,824股。最後,Private Advisor Group LLC在第二季度將其在Catalent的頭寸增加了98.5%。Private Advisor Group LLC在此期間又購買了2,913股,現在擁有5870股該公司股票,價值630,000美元。99.38%的股票由對衝基金和其他機構投資者持有。
Catalent Company Profile
Catalent公司簡介
(Get Rating)
(獲取評級)
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Catalent公司及其子公司在全球範圍內開發和製造藥物、基於蛋白質的生物製劑、細胞和基因療法以及消費者保健產品的解決方案。軟凝膠和口腔技術部門提供用於一系列客户產品的軟膠囊的配方、開發和製造服務,如處方藥、非處方藥、膳食補充劑、單位劑量化粧品和動物保健藥物製劑。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- 免費獲取StockNews.com關於Catalent的研究報告(CTLT)
- AMD仍是市面上最好的半導體股票之一
- 兩大股利大王:強生還是雅培?
- 網絡安全類股已經見底了嗎?
- 聯合太平洋,諾福克南方進入購買區
- 柔順治療公司的差距增加了34%:未來還會有更多的好處嗎?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Catalent Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Catalent和相關公司的最新新聞和分析師評級的每日簡要摘要。